BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

First published online May 30, 2007
British Journal of Radiology (2007) 80, 508-515
© 2007 British Institute of Radiology
doi: 10.1259/bjr/17395663

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veit-Haibach, P
Right arrow Articles by Bockisch, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veit-Haibach, P
Right arrow Articles by Bockisch, A

Full paper

FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy

P Veit-Haibach, MD1, G Antoch, MD1, T Beyer, PhD2, H Stergar, MD2, R Schleucher, MD3, E A M Hauth, MD1 and A Bockisch, MD, PhD2

Departments of 1 Diagnostic and Interventional Radiology and Neuroradiology, 2 Nuclear Medicine and 3 Oncology, University Hospital Essen, Essen, Germany

Correspondence: Dr Patrick Veit-Haibach, Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, Essen 45122, Germany. E-mail: patrick.veit{at}uni-essen.de

We aimed to compare the value of combined positron emission tomography (PET)/CT, PET+CT (viewed side by side), CT alone and PET alone concerning the rTNM stage and influence on therapy in patients with recurrent breast cancer. 44 patients with suspicion of recurrent breast cancer underwent whole-body [18F]-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT. Images of combined PET/CT, PET+CT, PET alone and CT alone were evaluated by four blinded reader teams. Diagnostic accuracies and influence on therapy were compared. Histology and a mean clinical follow up of 456 days served as the standard of reference. Differences between the staging procedures were tested for statistical significance by McNemar's test. Overall TNM tumour stage was correctly determined in 40/44 patients with PET/CT, in 38/44 with PET+CT, in 36/44 with PET alone and in 36/44 patients with CT alone. No statistically significant difference was detected between all tested imaging modalities. PET/CT changed the therapy in two patients compared with PET+CT, in four patients compared with PET alone and in five patients compared with CT alone. Combined PET/CT appeared to be more accurate in assessing the rTNM and showed a moderate impact on therapy over PET and CT. Minor improvements were noted when compared with PET+CT. Experienced readers might therefore be able to provide accurate staging results for further therapy from separately acquired studies.




This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
BJR review of the year -- 2007
Br. J. Radiol., April 1, 2008; 81(964): 265 - 269.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2007 by the British Institute of Radiology.